NRC Health Amends Executive Equity Grants, Eliminates Repurchase Rights, and Awards $2.8M in Tax Bonuses

summarizeSummary

NRC Health filed an amended 10-K, revealing significant changes to executive equity compensation in April 2026, including the elimination of repurchase rights on substantial share grants for the CEO and other executives, accompanied by $2.8 million in cash bonuses to cover estimated taxes.

check_boxKey Events

• Executive Equity Grants Amended

  Repurchase rights were eliminated on 700,000 shares for CEO Trent Green (500,000 shares), Helen Hrdy (100,000 shares), and Andy Monnich (100,000 shares). These shares, valued at over $11.7 million at current prices, were previously subject to company repurchase for $1.00 under certain termination conditions, making them less restricted.

• Substantial Cash Bonuses Awarded

  Cash bonuses totaling $2.8 million were approved for CEO Trent Green ($1.86M), Helen Hrdy ($483k), and Andy Monnich ($483k). These bonuses are intended to cover estimated tax liabilities associated with the amended equity awards.

• Delinquent Insider Filings

  Multiple Section 16(a) reports were filed late for key individuals including Patrick Beans, Jason Rau, and CFO Shane Harrison, indicating lapses in compliance.

• Significant 2025 Executive Compensation

  CEO Trent Green received $11.96 million in total compensation for 2025, including a $4.5 million cash bonus and $6.75 million in stock awards, reflecting a major investment in new leadership.

auto_awesomeAnalysis

This amended 10-K provides critical updates on executive compensation, particularly the April 2026 amendments to 2025 equity grants for CEO Trent Green, Helen Hrdy, and Andy Monnich. The elimination of company repurchase rights on 700,000 shares (valued at over $11.7 million at current prices) effectively de-risks these awards for executives and is accompanied by $2.8 million in cash bonuses to cover estimated tax obligations. While intended to align executive interests with shareholders, this move could be perceived negatively as it sweetens existing compensation without new performance triggers. Additionally, the filing discloses multiple delinquent Section 16(a) reports for key individuals, raising concerns about corporate governance and compliance. Investors should monitor the impact of these compensation structures on executive performance and the company's overall financial health, especially in light of recent positive revenue growth.